Global Blood Plasma Derivatives Market Size Projected to Reach $104.30 Billion by 2033; Immunoglobulins Drive Robust 9.08% CAGR – SNS Insider
Surging prevalence of rare immune disorders, advancements in AI-driven fractionation, and rapid expansion of plasma collection networks in Asia-Pacific propel the industry toward high-growth trajectories.
Austin, United States, Feb. 19, 2026 (GLOBE NEWSWIRE) — Blood Plasma Derivatives Market Size & Growth Analysis:
According to SNS Insider, The Blood Plasma Derivatives Market size was valued at $52.16 Billion in 2025 and is expected to reach $104.30 Billion by 2033, growing at a CAGR of 9.08 from 2026 to 2033.”
The market is witnessing strong growth driven by the increasing incidence of immune deficiencies, hematological disorders, and neurological disorders. The International Labor Organization and various global health bodies have emphasized the importance of plasma-derived therapies like immunoglobulins, coagulation factors, and albumin. Demand for blood plasma derivatives was at 145 million liters in 2025, indicating strong growth driven by increasing immunoglobulin usage and plasma collection infrastructure in key markets.
Market Size and Forecast:
- Market Size in 2025: $52.16 Billion
- Market Size by 2033: $104.30 Billion
- CAGR: 9.08% from 2026 to 2033
- Base Year: 2025
- Forecast Period: 2026–2033
- Historical Data: 2022–2024
Get a Sample Report of Blood Plasma Derivatives Market: https://www.snsinsider.com/sample-request/9142
The U.S. Blood Plasma Derivatives Market was valued at $17.06 Billion in 2025 and is projected to reach $33.54 Billion by 2033, growing at a CAGR of 8.85% over the forecast period. The presence of plasma donation infrastructure, rising utilization of immunoglobulin treatment for chronic as well as neurological disorders, and continuous investments in R&D activities by major players in the global biopharmaceutical market are some of the factors driving the market growth. Growing reimbursement and clinical acceptance of plasma-based therapy are accelerating product penetration within major healthcare facilities.
Major Players Analysis Listed in this Report are:
- CSL Limited
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Baxter International Inc.
- Octapharma AG
- Kedrion S.p.A.
- LFB Group
- Biotest AG
- China Biologic Products Holdings, Inc.
- ADMA Biologics, Inc.
- Green Cross Corporation
- Fusion Health Care Pvt. Ltd.
- SK Plasma Co., Ltd.
- Bayer AG
- Sanquin (Netherlands)
- Hualan Biological Engineering Inc.
- Intas Pharmaceuticals Ltd.
- BDI Pharma
- Shanghai RAAS Blood Products Co., Ltd.
- Swedish Orphan Biovitrum AB
Segmentation Analysis:
By Product Type
Immunoglobulins held the largest market share of 41.28% in 2025 as they had been widely being used to treat immune deficiencies, autoimmune diseases & infections. Fibrinogen Concentrate is expected to grow at the fastest CAGR of 10.74% during 2026–2033 as it can be used to control trauma and surgical bleeding.
By Source
Human Plasma dominated with a 67.85% share in 2025 as they have demonstrated safety and proven to be trustworthy in generating therapeutic proteins. Recombinant is projected to expand at the fastest CAGR of 11.29% during the forecast period as it removes the risk of infection and reliance on human donors.
By Application
Immunology accounted for the highest market share of 38.62% in 2025 supported by increasing incidence of immunodeficiency diseases and autoimmune disorders. Neurology is anticipated to record the fastest CAGR of 9.97% through 2026–2033 due to the increasing use in in neuropathy, plasma-derive day treatments globally.
By End User
Hospitals & Clinics held the largest share of 54.43% in 2025 incorporating as the main centers for plasma therapy, with advanced diagnostic products and well-established patient care processes. Research Institutes are expected to grow at the fastest CAGR of 8.86% during 2026–2033 as clinical trials expand and academic joint ventures with biopharmaceutical corporations have multiplied.
Need Any Customization Research on Blood Plasma Derivatives Market, Enquire Now: https://www.snsinsider.com/enquiry/9142
Key Blood Plasma Derivatives Market Segments
By Product Type
- Albumin
- Immunoglobulins
- Coagulation Factors
- Protease Inhibitors
- Fibrinogen Concentrate
- Others
By Source
- Human Plasma
- Recombinant
By Application
- Immunology
- Hematology
- Critical Care
- Neurology
- Others
By End User
- Hospitals & Clinics
- Diagnostic Centers
- Research Institutes
- Others
Regional Insights:
The North America dominated the Blood Plasma Derivatives Market with a 39.57% share, owing to investment in healthcare infrastructure and high plasma therapy utilization rate U.S and Canada.
The Asia-Pacific Blood Plasma Derivatives Market is the fastest-growing region, projected to expand at a CAGR of 10.89% during 2026–2033. Increased demand in China, Japan, India and South Korea for healthcare infrastructure and increased awareness toward plasma therapies (including IVIG) are the major factors that spur growth.
Recent Developments:
- In April 2025, CSL unveiled its state-of-the-art plasma fractionation Facility F in Broadmeadows, Australia. Featuring full automation and robotics, the plant enhances plasma processing capacity to over 10 million litres annually, boosting CSL’s leadership in plasma-derived therapies and manufacturing excellence.
- In October 2025, Takeda launched HyHub and HyHub Duo devices in the U.S. for use with its plasma-derived immunoglobulin therapy HYQVIA. The devices simplify infusion preparation, reduce steps and ancillary supplies, and enhance patient mobility during treatment.
Exclusive Sections of the Report (The USPs):
- PRODUCTION EFFICIENCY & FRACTIONATION METRICS – helps you understand plasma fractionation efficiency, recovery yield consistency, and processing cycle time across large-scale manufacturing units. Also evaluates batch reproducibility and standardization levels to assess production scalability and operational control.
- UTILIZATION & CLINICAL APPLICATION INDICATORS – helps you analyze consumption frequency across therapeutic and diagnostic applications along with utilization efficiency in hospitals and laboratories. Also measures storage stability and shelf-life performance under long-term controlled medical environments.
- SUPPLY CHAIN DISRUPTION INDEX – helps you identify risks across temperature-sensitive transportation, inventory turnover duration, and manufacturing-to-end-user lead times. Also evaluates distribution reliability and stock replenishment efficiency across healthcare networks.
- QUALITY & SAFETY COMPLIANCE METRICS – helps you assess purity and potency verification standards along with viral inactivation and sterilization efficiency benchmarks. Also measures compliance with pharmacopoeial regulations and batch validation performance before distribution.
- CAPACITY UTILIZATION RATES – helps you determine whether plasma processing facilities are operating at optimal throughput levels or facing underutilization constraints. Also supports investment planning by analyzing production scalability and demand alignment.
- COMPETITIVE LANDSCAPE & OPERATIONAL BENCHMARKING – helps you gauge the competitive strength of key plasma derivative manufacturers based on production efficiency, quality compliance, and distribution capabilities. Also analyzes operational differentiation and expansion strategies across global markets.
Purchase Single User PDF of Blood Plasma Derivatives Market Report (20% Discount): https://www.snsinsider.com/checkout/9142
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Market Overview
4. Statistical Insights & Trends Reporting
5. Blood Plasma Derivatives Market Segmental Analysis & Forecast, By Product Type
6. Blood Plasma Derivatives Market Segmental Analysis & Forecast, By Source
7. Blood Plasma Derivatives Market Segmental Analysis & Forecast, By Application
8. Blood Plasma Derivatives Market Segmental Analysis & Forecast, End-User
9. Blood Plasma Derivatives Market Segmental Analysis & Forecast, By Region
10. Competitive Landscape
11. Analyst Recommendations
12. Assumptions
13. Disclaimer
14. Appendix
Access Complete Report Details of Blood Plasma Derivatives Market Analysis & Outlook: https://www.snsinsider.com/reports/blood-plasma-derivatives-market-9142
[For more information or need any customization research mail us at [email protected]]
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: [email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. UKNewshour.com takes no editorial responsibility for the same.
